Overview

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals

Phase:

Phase 1

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Aripiprazole